RossouwJEAndersonGLPrenticeRLRisks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA2002;288(3):321–33.
2.
BestulMBMcCollumMHansenLBImpact of the Women's Health Initiative trial results on hormone replacement therapy. Pharmacotherapy2004;24(4):495–9.
3.
MoskowitzD. A comprehensive review of the safety and efficacy of bioidentical hormones for the management of menopause and related health risks. Altern Med Rev2006;11(3):208–23.
4.
BoothbyLADoeringPLKipersztokS. Bioidentical hormone therapy: a review. Menopause2004;11(3):356–67.
5.
LangeCA. Challenges to defining a role for progesterone in breast cancer. Steroids2008;73(9-10):914–21.
6.
AdamsCCannelS. Women's beliefs about “natural” hormones and natural hormone replacement therapy. Menopause2001;8(6):433–40.
7.
VigesaaKADownhourNPChuiMAEfficacy and tolerability of compounded bioidentical hormone replacement therapy. Int J Pharm Comp2004;8(4):313.
8.
BosargePMFreemanS. Bioidentical hormones, compounding and evidence-based medicine: what women's health practitioners need to know. J Nurse Practitioner2009;5(6):421–7.
9.
BoothbyLADoeringPL. Bioidentical hormone therapy: a panacea that lacks supportive evidence. Curr Clin Obstet Gynecol2008;20:400–7.
10.
TakahashiKManabeAOkadaMEfficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas2000;34(2):169–77.
11.
PriorJCHitchcockCL. Progesterone for vasomotor symptoms: a 12-week randomized, masked placebo-controlled trial in healthy, normal-weight women 1–10 years since final menstrual flow [abstract]. Endocr Rev2010;31(3 Supp1):S19–2.
12.
KuhlH. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric2005;8Suppl 1:3–63.
13.
LeonettiHBLongoSAnastiJN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol1999;94(2):225–8.
14.
WrenBGChampionSMWillettsKTransdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause2003;10(1):13–8.
15.
BensterBCareyAWadsworthFA double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women. Menopause Int2009;15(2):63–9.
SantenRJAllredDCArdoinSPPostmenopausal hormone therapy: an endocrine society scientific statement. J Clin Endocrinol Metab2010;95(Suppl 1):S1–S66.
18.
ItoiHMinakamiHSatoI. Comparison of the long-term effects of oral estriol with the effects of conjugated estrogen, 1-alpha-hydroxyvitamin D3 and calcium lactate on vertebral bone loss in early menopausal women. Maturitas1997;28(1):11–7.
19.
TerauchiMObayashiSAsoT. Estriol, conjugated equine estrogens, and alendronate therapy for osteoporosis. Int J Gynaecol Obstet2006;92(2):141–2.
20.
BensterBCareyAWadsworthFDouble-blind placebo-controlled study to evaluate the effect of pro-juven progesterone cream on atherosclerosis and bone density. Menopause Int2009;15(3):100–6.
21.
PanayNFentonA. Bioidentical hormones: what is all the hype about?Climacteric2010;13:1–3.
22.
ItoiHMinakamiHIwasakiRComparison of the long-term effects of oral estriol with the effects of conjugated estrogen on serum lipid profile in early menopausal women. Maturitas2000;36(3):217–22.
23.
North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement. Menopause2010;17(2):242–55.
24.
The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women — The Postmenopausal Estrogens/Progestin Intervention (PEPI) Trial. JAMA1996;275:370–5.
25.
GranbergSEureniusKLindgrenRThe effects of oral estriol on the endometrium in postmenopausal women. Maturitas2002;42(2):149–56.
26.
WeiderpassEBaronJAAdamiHOLow-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet1999;353(9167):1824–8.
27.
CareyBJCareyAHPatelSA study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women. BJOG2000;107(6):722–6.
28.
VashishtAWadsworthFCareyAA study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. Gynecol Endocrinol2005;21(2):101–5.
29.
LeonettiHBWilsonKJAnastiJN. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril2003;79(1):221–2.
30.
WrenBGMcFarlandKEdwardsLEffect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric2000;3(3):155–60.
31.
VashishtAWadsworthFCareyABleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. BJOG2005;112(10):1402–6.
32.
EdenJAHackerNFFortuneM. Three cases of endometrial cancer associated with bioidentical hormone replacement therapy. Med J Aust2007;187:244.
33.
LippmanMMonacoMBohanC. Effects of estrone, estradiol, and estriol on hormone responsive human breast cancer in long term culture. Cancer Res1977; 37:1901–7.
34.
MelamedMCastanoENotidesACMolecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol1997;11(12):1868–78.
35.
FournierAFabreAMesrineSUse of different postmenopausal hormone therapies and risk of histology and hormone receptor-defined invasive breast cancer. J Clin Oncol2008;26:1260–8.
36.
CollinsJJ. The value of hormone assessment. Int J Pharm Comp2001;5(5):342.
37.
WoodP. Salivary steroid assays — research or routine?Ann Clin Biochem2009;46(Pt 3):183–96.
